VIDEO: Baricitinib long-term efficacy data in alopecia areata highlight of AAD 2023
Click Here to Manage Email Alerts
NEW ORLEANS — In this Healio exclusive video, Brett King, MD, PhD, discusses results from the BRAVE-AA1 and BRAVE-AA2 phase 3 clinical trials of baricitinib for patients with alopecia areata.
The study by Maryanne M. Senna, MD, and colleagues, was presented at the American Academy of Dermatology Annual Meeting.
“This is really important data because this is a chronic disease; we need data over a long period of time,” King, associate professor of dermatology at Yale University School of Medicine in New Haven, Connecticut, said.
King noted that 90% of patients achieved a Severity of Alopecia Tool (SALT) score of 20 or less at the baricitinib 4 mg dose at 52 weeks, and this score was maintained through 104 weeks. The study also found that patients taking baricitinib 2 mg dose who achieved a SALT score of 20 or less at 52 weeks also maintained minimal scalp hair loss.
“This is helping us manage our patients,” King said.
Collapse
Senna M, et al. Long-term efficacy of baricitinib in alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. Presented at: American Academy of Dermatology Annual Meeting; March 17-21, 2023; New Orleans.
Read more about
Click Here to Manage Email Alerts